Tezepelumab for Moderate to Very Severe COPD
This study is testing a drug called tezepelumab to see if it can help adults with moderate to very severe Chronic Obstructive Pulmonary Disease (COPD). Participants will receive either tezepelumab or a placebo (an inactive substance) as a shot under the skin. The main goal is to see if tezepelumab can reduce the number of moderate or severe COPD flare-ups (exacerbations) over about 76 weeks. You might be able to join if you are 40 to 80 years old, have had COPD for at least a year, and have experienced at least two moderate or one severe COPD flare-up in the past year. The study is currently not recruiting, as its status is unclear.
- Study design
- This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study involving about 990 participants.
- What's involved
- Participants will receive monthly subcutaneous injections for a maximum of 76 weeks and a minimum of 52 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- There is a 12-week safety follow-up period after treatment ends.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
At a glance
Conditions
Where it's being run
268 sites across 48 statesStudy leadership
- MeiLan Han, MD · PRINCIPAL_INVESTIGATOR · University of Michigan Health, Pulmonary & Critical Care Medicine,
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Exclusion
What this trial measures
- Annualised rate of moderate or severe COPD exacerbationsBaseline up to 76 weeks
The annualised moderate or severe COPD exacerbation rate (based on exacerbations reported by the investigator) up to 76 weeks treatment period compared to placebo.